Accenture (ACN) Completes Acquisition of Homburg & Partner
Accenture plc ACN has acquired strategic management consulting firm Homburg & Partner for an undisclosed amount.
With in-depth specialization in commercial strategy, sales and pricing, Homburg & Partner largely serves clients in healthcare, chemical and industrial goods industries. The company has the experience of working with large and mid-sized firms on projects such as developing go-to-market strategies, implementing leading pricing methodologies, and optimizing sales processes and organizations.
How Will Accenture Benefit?
The buyout is expected to boost Accenture’s strategy and process capabilities predominantly in the areas of commercial strategy, sales and pricing methods, and knowledge, better positioning the company for client’s value creation.
According to Edwin van der Ouderaa, global lead of Customer, Sales & Service at Accenture, "The addition of Homburg & Partners expands our ability to shape growth and efficiency strategies across the enterprise and will increase our clients’ focus on growing their sales and profits, as they pivot to their next generation customer engagement."
Notably, Accenture shares have gained 45.2% over the past year, outperforming the 41.8% growth of the Zacks S&P 500 composite, while underperforming the 48.7% rally of the industry it belongs to.
Zacks Rank and Stocks to Consider
Accenture currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Some better-ranked stocks in the broader Zacks Business Services sector are Genpact G, Equifax EFX and TransUnion TRU, each carrying a Zacks Rank #2 (Buy).
The long-term expected earnings per share (three to five years) growth rate for Genpact,Equifax and TransUnion is 12.8%, 14% and 20.9%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Equifax, Inc. (EFX) : Free Stock Analysis Report
Accenture PLC (ACN) : Free Stock Analysis Report
Genpact Limited (G) : Free Stock Analysis Report
TransUnion (TRU) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
